Targeted and novel therapy in advanced gastric cancer.

Hideo Saka, Chiyoe Kitagawa, Yoshihito Kogure, Yasuo Takahashi, Koshi Fujikawa, Tamotsu Sagawa, Satoru Iwasa, Naoki Takahashi, Taro Fukao, Catherine Tchinou, Dónal Landers, Yasuhide Yamada, Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study Investigational New Drugs. ,vol. 35, pp. 451- 462 ,(2017) , 10.1007/S10637-016-0416-X

, Integrated genomic characterization of oesophageal carcinoma. Nature. ,vol. 541, pp. 169- 175 ,(2017) , 10.1038/NATURE20805

Bin-Chi Liao, Chia-Chi Lin, James Chih-Hsin Yang, Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Current Oncology Reports. ,vol. 19, pp. 4- ,(2017) , 10.1007/S11912-017-0560-2

YJ Bang, G Giaccone, SA Im, DY Oh, TM Bauer, JL Nordstrom, H Li, GR Chichili, PA Moore, S Hong, SJ Stewart, JE Baughman, RJ Lechleider, HA Burris, None, First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors Annals of Oncology. ,vol. 28, pp. 855- 861 ,(2017) , 10.1093/ANNONC/MDX002

Yelena Yuriy Janjigian, Marinela Capanu, Christopher M Gromisch, David Paul Kelsen, Geoffrey Y Ku, Karen T Brown, Mark Schattner, David H Ilson, David B Solit, Michael F Berger, Efsevia Vakiani, A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer. Journal of Clinical Oncology. ,vol. 31, pp. 52- 52 ,(2013) , 10.1200/JCO.2015.33.3_SUPPL.59

Ana Maria Autran-Gomez, Fernando P. Secin, Arjun Sivaraman, Rafael Sanchez-Salas, Juan I Monzo, Dominic Prapotnich, Eric Barret, Francois Rozet, Marc Galiano, Annick Mombet, Nathalia Cathala, Xavier Cathelineau, Predictors of pathological upgrading and upstaging in patients eligible for active surveillance submitted to radical prostatectomy (RARP). Journal of Clinical Oncology. ,vol. 33, pp. 59- 59 ,(2015) , 10.1200/JCO.2015.33.7_SUPPL.59

Daisuke Takahari, Second-line chemotherapy for patients with advanced gastric cancer Gastric Cancer. ,vol. 20, pp. 395- 406 ,(2017) , 10.1007/S10120-017-0707-8

Irina S Babina, Nicholas C Turner, None, Advances and challenges in targeting FGFR signalling in cancer Nature Reviews Cancer. ,vol. 17, pp. 318- 332 ,(2017) , 10.1038/NRC.2017.8

Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara, Gail D Lewis Phillips, Tina van der Horst, Marie-Laurence Harle-Yge, Betsy L Althaus, Yoon-Koo Kang, Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study The Lancet Oncology. ,vol. 18, pp. 640- 653 ,(2017) , 10.1016/S1470-2045(17)30111-0

Deirdre Jill Cohen, Paul J. Christos, Hedy Lee Kindler, Daniel Virgil Thomas Catenacci, Tanios B. Bekaii-Saab, Sanaa Tahiri, Yelena Yuriy Janjigian, Michael K. Gibson, Emily Chan, Lakshmi Rajdev, Susan Urba, James Lloyd Wade, Peter Kozuch, Erica Love, Katherine Vandris, Naoko Takebe, Howard S. Hochster, Joseph A. Sparano, , Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study. Journal of Clinical Oncology. ,vol. 31, pp. 4011- 4011 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.4011